MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance.

Vanessa Desantis, Ilaria Saltarella, Aurelia Lamanuzzi, Assunta Melaccio, Antonio Giovanni Solimando, Maria Addolorata Mariggiò, Vito Racanelli, Angelo Paradiso, Angelo Vacca, Maria Antonia Frassanito

Research output: Contribution to journalReview articlepeer-review

Abstract

MicroRNAs (miRNAs, or miRs) are single-strand short non-coding RNAs with a pivotal role in the regulation of physiological- or disease-associated cellular processes. They bind to target miRs modulating gene expression at post-transcriptional levels. Here, we present an overview of miRs deregulation in the pathogenesis of multiple myeloma (MM), and discuss the potential use of miRs/nanocarriers association in clinic. Since miRs can act as oncogenes or tumor suppressors, strategies based on their inhibition and/or replacement represent the new opportunities in cancer therapy. The miRs delivery systems include liposomes, polymers, and exosomes that increase their physical stability and prevent nuclease degradation. Phase I/II clinical trials support the importance of miRs as an innovative therapeutic approach in nanomedicine to prevent cancer progression and drug resistance. Results in clinical practice are promising.

Original languageEnglish
Article number3084
JournalInt J Mol Sci
Volume21
Issue number9
DOIs
Publication statusPublished - Apr 27 2020

Keywords

  • Animals
  • Disease Progression
  • Drug Resistance, Neoplasm/genetics
  • Exosomes
  • Gene Expression Regulation, Neoplastic
  • Gene Transfer Techniques
  • Humans
  • Lipids/chemistry
  • Liposomes
  • MicroRNAs/genetics
  • Multiple Myeloma/genetics
  • Nanotechnology/methods
  • Polymers/chemistry
  • RNAi Therapeutics/methods

Fingerprint

Dive into the research topics of 'MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance.'. Together they form a unique fingerprint.

Cite this